Chinese
English
Company Profile
Company Profile
Founded in August 1995 and located in Qianxinan High‑Tech Industrial Development Zone, Guizhou Tiandi Pharmaceutical Co., Ltd. is a modern pharmaceutical enterprise integrating the R&D, production and sales of injections. It features eco‑friendly, automated and intelligent production strengths.
The company employs over 500 employees and is equipped with complete professional production lines. It owns 4 production lines for large‑volume injections with 22 specifications and 3 production lines for small‑volume injections with 12 specifications. The annual production capacity reaches 360 million bottles of large‑volume injections and 1 billion vials of small‑volume injections. Its sales network covers 18 provinces and autonomous regions across China including Guizhou, Yunnan, Guangxi and Guangdong. Meanwhile, it provides customized pharmaceutical OEM services, with products sold far to many countries and regions in South America, Africa and Asia.
Since 2020, amid profound industrial changes and fierce market competition, the company has proactively adjusted its development strategy and accelerated international layout, focusing on exploring markets in Global South countries. It has successively passed GMP factory inspection and certification in Yemen, Ethiopia, Nigeria, Uzbekistan, Pakistan, the Philippines, Iraq and other countries, with nearly 70 pharmaceutical varieties registered and filed overseas. Maintaining steady operation, the enterprise achieves an average annual tax‑inclusive sales revenue of about 300 million yuan and pays over 15 million yuan in taxes each year over the past five years. It earnestly fulfills social responsibilities and boosts local economic development. In 2026, the company continues to advance technological transformation and upgrading to ensure stable market supply and sustain sound business performance.
For the next five years, the company will seize policy opportunities to improve quality and expand scale in multiple dimensions. It will capitalize on the development of the national unified large market, participate in standardized fair competition domestically, and effectively vitalize and release surplus production capacity. Supported by high‑level opening‑up, it will further explore emerging overseas markets and optimize capacity allocation, stabilizing the annual capacity of large‑volume injections at 250 million bottles. It will carry out technological upgrading and capacity expansion for small‑volume injections to raise production capacity by more than 50% to 1.6–1.8 billion vials per year. Comprehensive digital and intelligent transformation of production and operation will be promoted to streamline management processes, cut costs, improve efficiency and strengthen overall competitiveness. The company will scale up new drug R&D and registration application at home and abroad, optimize product mix, and precisely meet clinical medication needs worldwide. Centering on its development goals, it strives to achieve a breakthrough of 1 billion yuan in tax‑inclusive sales revenue during the 15th Five‑Year Plan period.
Standing at a new development stage, the company will strictly uphold quality standards and pursue refined pharmaceutical manufacturing. It is committed to building itself into a large‑scale domestic manufacturer of essential medicines and a key international production base for injection exports, and striving to become a high‑quality and efficient injection producer and comprehensive service provider. It will continue to contribute to the advancement of the medical and health industry as well as the high‑quality economic and social development of the local region.
Introduction to Subsidiaries
Introduction to Guizhou Guande Real Estate Development Co., Ltd.
Guizhou Guande Real Estate Development Co., Ltd. is a wholly-owned subsidiary of Guizhou Tiandi Pharmaceutical Co., Ltd., established on August 4, 2017, with a registered capital of 10 million yuan. It is located at No. 1 Fengyi Road, Fengdu Subdistrict Office, Xingyi City, Qianxinan Prefecture, Guizhou Province. It is adjacent to the national-level scenic spot of Malinhhe Canyon and the Wanfo Forest, with beautiful scenery, pleasant environment, and convenient transportation.
The real estate project developed by Guizhou Guande Real Estate Development Co., Ltd. is "Guande Huating" (Record name: Guizhou Guande Garden Residential Community). The project is located at No. 1 Fengyi Road, Fengdu Street Office, Xinyi City, Qiannan Buyi and Miao Autonomous Prefecture, Guizhou Province, situated between Civil Aviation Avenue and Fengyi Road, south facing Fengyi Road, north adjacent to Civil Aviation Avenue, east connecting Shida Osmanthus Garden, and west neighboring Mingye Primary School.
“The "Guande Huating" community is surrounded by complete supporting facilities, with a middle school, primary school, and pharmacy all within a 200-meter radius. It is a mature residential community, located 2 kilometers from Xingyi Airport, 2 kilometers from the under-construction high-speed railway south station, 2 kilometers from the city's main thoroughfare (expressway) Fengdu Avenue, and 1.5 kilometers from Longtang Avenue, adjacent to Civil Aviation Road and Wanfeng Avenue.
“The Guande Huating land area is 98,634.03 square meters (147.95 acres), with a building footprint of 21,676.21 square meters and a total construction area of 339,477.45 square meters, and a calculated building area of 256,498.07 square meters. The area of the clubhouse is 2,632.73 square meters, the kindergarten area is 3,480.03 square meters, the commercial building area is 20,874.32 square meters, and the residential building area is 228,862.32 square meters. The non-calculated building area is 82,979.38 square meters, with a maximum number of floors of 18 and a maximum height of 59.3 meters, capped at 60 meters. The floor area ratio is 3.0, and the green space ratio is 35.29%.
The project planning and design emphasize the principle of "people-centered," striving to develop the community into a fourth-generation residential area with a beautiful living environment, complete supporting facilities, and rich cultural connotation. The community is divided into three sections arranged in three clusters. The first cluster, buildings 6-9#, consists of a commercial square formed by four towers and eight units; the second cluster, buildings 1-5#, is an enclosed courtyard-style group formed by five towers, ten units, and a clubhouse; the third cluster, buildings 10-22#, comprises an open residential group with twelve residential buildings and a kindergarten. There are a total of 1,562 residential units and 2,052 underground parking spaces. The first and second clusters, along with the kindergarten, have been completed and are in use, while the third cluster has not yet commenced construction.
“The "Guande Huating" community features an open view, abundant natural water resources, and a pure natural charm, making it the preferred place for home living.
Introduction to Guizhou Tiandi Pharmaceutical Packaging Materials Co., Ltd.
Guizhou Tiandi Pharmaceutical Packaging Materials Co., Ltd. is an innovative enterprise engaged in the production of pharmaceutical packaging materials and a wholly-owned subsidiary of Guizhou Tiandi Pharmaceutical Co., Ltd. It was established in October 2010 and is located in the Hongxing Industrial Park of Dingxiao Town, Xingyi City, Guizhou Province. Currently, its production capacity includes an annual output of 500 million plastic bottle PP combination caps for infusion, 200 million soft bag infusion connectors, and other related supporting products, with nearly 60 employees.
Since its establishment, the company has built a professional production quality management team and a stable technical talent pool by attracting skilled professionals. All employees strictly adhere to national standards in the production of pharmaceutical packaging products, providing high-quality supporting packaging materials to the headquarters, Guizhou Tiandi Pharmaceutical Co., Ltd. At the same time, the company sells its products nationwide, with an annual output value of nearly 30 million yuan and annual tax contributions of 1.5 million yuan, making a positive contribution to the local economic and social development.
Looking to the future, the company will continue to adhere to the corporate management philosophy of "valuing quality as life and focusing on efficiency" and the corporate spirit of "civilization, standardization, practicality, and innovation," fully committed to providing high-quality packaging materials for pharmaceutical companies, and working together to "bravely undertake the social responsibilities required to serve the cause of human health."
Introduction to Guizhou Tiandi Pharmaceutical Import and Export Co., Ltd.
Guizhou Tiandi Medical Import and Export Co., Ltd. was registered on July 29, 2020. It is a wholly-owned subsidiary of Guizhou Tiandi Pharmaceutical Co., Ltd., with a registered capital of 5 million RMB. Its main business is the import and export of pharmaceuticals, with products primarily sold to countries and regions in South America, Africa, and Southeast Asia.
In 2020, due to the impact of the pandemic, Guizhou Tiandi Pharmaceutical established Guizhou Tiandi Pharmaceutical Import and Export Co., Ltd. to find a breakthrough for development. In the past three years, Guizhou Tiandi Pharmaceutical Import and Export Company has made great efforts to expand its entrusted processing and foreign export trade business, resulting in a significant increase in the company's sales revenue. In 2021, the total industrial output value of exports reached approximately 150 million yuan, and in 2022, it achieved nearly 100 million yuan in export industrial output value.
After three years of hard work and exploration during the pandemic, Guizhou Tiandi Medicine Import and Export Co., Ltd. has established a strategic pattern that penetrates the whole country and expands overseas, forming good cooperative relationships with some countries and regions in Southeast Asia. Now entering the post-pandemic era, Guizhou Tiandi Medicine Import and Export Co., Ltd. will continue to expand its overseas market business, improve its operational system, and strive to achieve a strategic layout for international market GMP certification.
Development process
-
- Optimize the organizational structure and establish the General Technology Department to provide professional technical support for improving production efficiency and ensuring product quality.
2025year
Health authorities of Uzbekistan, Nigeria, Iraq and other countries have successively conducted factory audits at the company. - Optimize the organizational structure and establish the General Technology Department to provide professional technical support for improving production efficiency and ensuring product quality.
-
- The enterprise has obtained international pharmaceutical production quality certification certificates issued by Ethiopia, the Philippines and Yemen.
2024year
Nearly 50 products have been registered in more than ten countries including Nigeria, Peru and Uzbekistan, laying a solid foundation for accessing global markets. - The enterprise has obtained international pharmaceutical production quality certification certificates issued by Ethiopia, the Philippines and Yemen.
-
- While consolidating the domestic sales market, the company has further expanded customized OEM processing and export business, with the proportion of foreign trade continuing to grow.
2023year -
- Guizhou Tiandi Pharmaceutical Import and Export Co., Ltd. was established, and foreign trade sales revenue accounted for more than half of the total sales revenue.
2020year -
- Complete the change of production addresses of all registered varieties and re-registration work, and complete the GMP certification work of four production workshops.
2019year -
- Overall, it has settled in the Hongxing Pharmaceutical Industrial Park in Yilong New District.
2018year -
- In accordance with the needs of Xingyi City’s urban planning development and national environmental protection requirements, with the care and strong support of party committees, governments and relevant functional departments at all levels of provinces, prefectures, municipalities and districts, Tiandi Pharmaceutical has launched an overall off-site relocation project.
2017year -
- The sixth phase of GMP technical transformation project of "large-capacity injection H production line (plastic bottle packaging) and soft bag infusion production line" was implemented, and the varieties of large-capacity injection were once again improved, and the packaging forms include glass bottles, plastic bottles, and soft bags.
2014-2016year -
- Implement the fifth phase of the GMP technical transformation project of "Large-capacity injection F and G production lines (plastic bottle packaging) production lines". In addition to glass bottle packaging, plastic bottle packaging has been added.
2012-2013year -
- The annual sales revenue exceeded 400 million yuan.
2009year -
- The fourth phase of the technical transformation project was completed, with sales revenue of 303 million yuan throughout the year, and more than 15.2 million yuan in taxes were paid to the state, ranking fourth in Xingyi City's industrial enterprise tax payments.
2008year -
- Implement the fourth phase technical transformation project of "Large-capacity injection D and E production lines".
2007year -
- Complete the construction of the third phase of technical transformation project.
2006year -
- Implement the third phase technical transformation project of "Large-capacity injection C production line and small-capacity injection production line". At the same time, sales revenue exceeded 100 million yuan, achieved profits and taxes of 12.94 million yuan, achieved the production and operation goal of 280 million bottles of large infusions throughout the year, achieved profits of more than 10 million yuan, and paid taxes of more than 10 million yuan;
2005year -
- Implement the two-step strategy of "increasing technical transformation efforts, expanding production scale, increasing product research and development efforts, and continuously improving the variety structure", add 7 new infusion varieties, add therapeutic large-capacity injection varieties on the basis of basic large-capacity injections, complete the second phase of the "Large-capacity injection B production line", and "the history of one workshop, one dosage form, and a single variety" has been refreshed.
2004year -
- The company carried out asset restructuring, and after the restructuring, the state-owned enterprise withdrew from its status, Guizhou Tiandi Pharmaceutical became a modern enterprise with a veritable corporate governance structure, and Chairman Liu Zhengchao took office.
2003year -
- An investment of 30 million yuan was made to implement the first GMP technical transformation project, a brand new factory with a construction area of 3,200 square meters and a modern large infusion production line with an annual production capacity of more than 30 million bottles were built, and at the same time, it successfully passed the first national GMP certification.
2000year -
- 3.7 million bottles of large infusions were produced, with a output value of 7.8 million yuan and a profit and tax of 1.21 million yuan. Data from the Provincial Bureau of Statistics shows that the company ranked first in the province in the production, sales and market share that year.
1997year -
- The large infusion production line with an annual output of 3 million bottles has passed the acceptance of the provincial competent department, making up for the gap in Qiannan Prefecture's production line without large infusion.
1996year -
- Tiandi Pharmaceutical has been registered and established to build a large infusion production line with an annual output of 3 million bottles;
1995year
-
2025year
- Optimize the organizational structure and establish the General Technology Department to provide professional technical support for improving production efficiency and ensuring product quality.
Health authorities of Uzbekistan, Nigeria, Iraq and other countries have successively conducted factory audits at the company. - Optimize the organizational structure and establish the General Technology Department to provide professional technical support for improving production efficiency and ensuring product quality.
-
2024year
- The enterprise has obtained international pharmaceutical production quality certification certificates issued by Ethiopia, the Philippines and Yemen.
Nearly 50 products have been registered in more than ten countries including Nigeria, Peru and Uzbekistan, laying a solid foundation for accessing global markets. - The enterprise has obtained international pharmaceutical production quality certification certificates issued by Ethiopia, the Philippines and Yemen.
-
2023year
- While consolidating the domestic sales market, the company has further expanded customized OEM processing and export business, with the proportion of foreign trade continuing to grow.
-
2020year
- Guizhou Tiandi Pharmaceutical Import and Export Co., Ltd. was established, and foreign trade sales revenue accounted for more than half of the total sales revenue.
-
2019year
- Complete the change of production addresses of all registered varieties and re-registration work, and complete the GMP certification work of four production workshops.
-
2018year
- Overall, it has settled in the Hongxing Pharmaceutical Industrial Park in Yilong New District.
-
2017year
- In accordance with the needs of Xingyi City’s urban planning development and national environmental protection requirements, with the care and strong support of party committees, governments and relevant functional departments at all levels of provinces, prefectures, municipalities and districts, Tiandi Pharmaceutical has launched an overall off-site relocation project.
-
2014-2016year
- The sixth phase of GMP technical transformation project of "large-capacity injection H production line (plastic bottle packaging) and soft bag infusion production line" was implemented, and the varieties of large-capacity injection were once again improved, and the packaging forms include glass bottles, plastic bottles, and soft bags.
-
2012-2013year
- Implement the fifth phase of the GMP technical transformation project of "Large-capacity injection F and G production lines (plastic bottle packaging) production lines". In addition to glass bottle packaging, plastic bottle packaging has been added.
-
2009year
- The annual sales revenue exceeded 400 million yuan.
-
2008year
- The fourth phase of the technical transformation project was completed, with sales revenue of 303 million yuan throughout the year, and more than 15.2 million yuan in taxes were paid to the state, ranking fourth in Xingyi City's industrial enterprise tax payments.
-
2007year
- Implement the fourth phase technical transformation project of "Large-capacity injection D and E production lines".
-
2006year
- Complete the construction of the third phase of technical transformation project.
-
2005year
- Implement the third phase technical transformation project of "Large-capacity injection C production line and small-capacity injection production line". At the same time, sales revenue exceeded 100 million yuan, achieved profits and taxes of 12.94 million yuan, achieved the production and operation goal of 280 million bottles of large infusions throughout the year, achieved profits of more than 10 million yuan, and paid taxes of more than 10 million yuan;
-
2004year
- Implement the two-step strategy of "increasing technical transformation efforts, expanding production scale, increasing product research and development efforts, and continuously improving the variety structure", add 7 new infusion varieties, add therapeutic large-capacity injection varieties on the basis of basic large-capacity injections, complete the second phase of the "Large-capacity injection B production line", and "the history of one workshop, one dosage form, and a single variety" has been refreshed.
-
2003year
- The company carried out asset restructuring, and after the restructuring, the state-owned enterprise withdrew from its status, Guizhou Tiandi Pharmaceutical became a modern enterprise with a veritable corporate governance structure, and Chairman Liu Zhengchao took office.
-
2000year
- An investment of 30 million yuan was made to implement the first GMP technical transformation project, a brand new factory with a construction area of 3,200 square meters and a modern large infusion production line with an annual production capacity of more than 30 million bottles were built, and at the same time, it successfully passed the first national GMP certification.
-
1997year
- 3.7 million bottles of large infusions were produced, with a output value of 7.8 million yuan and a profit and tax of 1.21 million yuan. Data from the Provincial Bureau of Statistics shows that the company ranked first in the province in the production, sales and market share that year.
-
1996year
- The large infusion production line with an annual output of 3 million bottles has passed the acceptance of the provincial competent department, making up for the gap in Qiannan Prefecture's production line without large infusion.
-
1995year
- Tiandi Pharmaceutical has been registered and established to build a large infusion production line with an annual output of 3 million bottles;
Company Rongyi
State-level health enterprises in 2022-2024
Development of advanced township enterprises in 2001
1999-2002 Civilized Unit
2000-2001 Civilized Unit in Qiannan Prefecture
2005 3A quality integrity unit
2006-2007 Qiannan Prefecture Civilized Unit
Integrity unit from 2005 to 2007
National advanced enterprises with double love and double evaluation in 2006
2002-2003 Civilized Unit in Qiannan Prefecture
2004-2005 Qiannan Prefecture Civilized Unit
2008-2011 Qiannan Prefecture well-known trademark
Class A tax credit enterprise from 2004 to 2006
Advanced Tax Payment Enterprises in 2004
Advanced Enterprises in Guizhou Province in 1997
Class A tax credit enterprise from 2006 to 2007
2003-2005 Advanced Working Unit for Spiritual Civilization Construction in the Province
Class A taxpayer in 2006
Establish an advanced unit for harmonious enterprise in 2006
Advanced Unit for the Construction of Spiritual Civilization in 2006 (2)
Advanced taxpayer enterprises in Xingyi City in 2006
Corporate culture
1、Corporate management philosophy：Consider quality as life, centered on efficiency。
2、Action Guide：Make conscience medicine and rest-satisfactory medicine to meet the medication needs of the majority of patients；
3、Corporate Spirit：Integrate knowledge and action, be craftsmanship and practical；
4、Business philosophy：Cooperation, win-win, development；
5、Quality policy：Comply with regulations, continuous improvement, high quality and efficiency, customer first；
6、Work spirit：Civilization, standardization, practicality, innovation；
7、Corporate values：Work hard and earnestly for oneself, innovate management to make profits for enterprises, and operate according to law to create wealth for society；
8、Service concept：Sincerity, trust, care, unity, responsibility；
9、Chairman's Creed：Quality wins customers, customers wins the market; market wins survival, and survival can develop；
10、Corporate Vision：Guizhou Tiandi Pharmaceutical is based on the existing production scale of basic drugs, giving full play to its own advantages, starting from cost control, structure adjustment, and mode transformation, and strives to develop into a regional pharmaceutical enterprise with large scale, good benefits, advanced management, leading technology, good brand effect and strong sustainable development capabilities, and make greater contributions to local economic and social development.。
organizational structure
Contact us
Company address: No. 6 Baokang Road, Hongxing Pharmaceutical Industrial Park, Dingxiao Town, Xingyi City, Qiannan Buyi and Miao Autonomous Prefecture, Guizhou Province.
Contact number (Administration): 0859-3116329
Contact number (Sales): 0859-3118152
Email: tdyy@gztiandi.com
WeChat Official Account
Copyright © 2024 贵州天地药业有限责任公司 版权所有 ICP备案号180006020号-3
